Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. - Wikidata - awgldk - TriplyDB

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

http://www.wikidata.org/entity/Q35111555

about

Renal effects of dapagliflozin in patients with type 2 diabetes The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials.Dapagliflozin in patients with type 2 diabetes mellitus.The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol).Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.Liver histone H3 methylation and acetylation may associate with type 2 diabetes development.Improved glycemic control in mice lacking Sglt1 and Sglt2.

P2860

Q24564811-A9580317-F41F-4E12-943B-848A66E64B8E Q30557454-BE0FEDB3-24B7-4A0A-8829-5B9DBFC5F0EB Q35064363-C4EF1C87-E7B3-499A-AD45-5D441F11D817 Q35141884-F1A17179-EE6E-48D4-921D-6DC704A23B9D Q37737454-A008C122-0737-4716-8CB1-2D4BAF8DD5F0 Q38075117-62CBA24B-51C2-49AC-95C0-AEE48A351B7F Q41457443-BA203401-141F-4D48-8DD8-397E6B28924F Q51349034-6A1FDD76-F555-432A-BF9C-7F075BD28925

P2860

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

http://www.wikidata.org/entity/Q35111555

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Dapagliflozin: a sodium glucos ...... velopment for type 2 diabetes.

@ast

Dapagliflozin: a sodium glucos ...... velopment for type 2 diabetes.

@en

type

label

Dapagliflozin: a sodium glucos ...... velopment for type 2 diabetes.

@ast

Dapagliflozin: a sodium glucos ...... velopment for type 2 diabetes.

@en

prefLabel

Dapagliflozin: a sodium glucos ...... velopment for type 2 diabetes.

@ast

Dapagliflozin: a sodium glucos ...... velopment for type 2 diabetes.

@en

P1433

Q35111555-C2982D67-73D8-494A-A013-DB22C18EF9E1

P1476

Q35111555-DE9D4645-7959-4852-84C1-167F1F6FD216

P2093

Q35111555-BCEEE814-2280-4BCF-A830-CFB605840D98

Q35111555-C5B7036E-0B91-4B0B-B20E-FFC3A83EB8CD

P2860

Q35111555-03812167-515D-4AD6-A28C-9A9C5528FDEB

Q35111555-05F62530-B6B6-43FD-9F64-938898185478

Q35111555-149E197C-FCCF-4735-9099-D61B427CD713

Q35111555-16BBF712-EF24-4A1F-85DB-806EB8785DAA

Q35111555-1E92FF8A-F650-4194-ABF5-CE85A5D450C1

Q35111555-22404929-5AD7-4EFA-90C8-831D6335F017

Q35111555-2821CD12-5F3F-4633-8C55-55C51B354015

Q35111555-32BE145E-EDB4-4289-BA30-68382A1AE45B

Q35111555-357138E6-448E-4435-8E29-93A5171FDD06

Q35111555-3D29796C-3B2D-410D-A7CC-AE111A42C8B1

P2888

Q35111555-9CD1AE83-1CC6-45DE-A6DF-94EAF00013E3

P304

Q35111555-435DE241-9BC1-4F06-990F-39903F6B5DBA

P31

Q35111555-13B5B4D6-FF5E-4B13-A666-D79EEA375D63

P356

Q35111555-4FE2CE8A-DCC7-4A25-999A-E5498FCAB7C0

P433

Q35111555-6D40819F-9BF8-41CB-BB3E-F03C7C455060

P478

Q35111555-66025120-A584-40F1-AB10-30D3B773A603

P577

Q35111555-2B6999A3-CCA8-4E8D-A81E-C6FF8B4E1549

P5875

Q35111555-19D3412F-E855-4E86-A4BB-8407D1B5D065

P698

Q35111555-E9BE259A-E11E-4E9B-9D6F-01F495BFADDD

P921

Q35111555-895388AB-8A16-4C9C-95C4-04F3DBAB87F0

P932

Q35111555-AA54EA9A-89AF-46AD-AAE5-4B9486616FA2

P356

S13300-010-0007-3

P1433

Diabetes Therapy

P1476

Dapagliflozin: a sodium glucos ...... velopment for type 2 diabetes.

@en

P2093

Abd A Tahrani

http://www.w3.org/2001/XMLSchema#string

Anthony H Barnett

http://www.w3.org/2001/XMLSchema#string

P2860

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Renal Na(+)-glucose cotransporters

Active sugar transport in health and disease

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development.

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.

Islet growth and development in the adult.

SGLT2 inhibition--a novel strategy for diabetes treatment.

P2888

s13300-010-0007-3

P304

45-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-010-0007-3

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51840507

http://www.w3.org/2001/XMLSchema#string

P698

22127745

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3138480

http://www.w3.org/2001/XMLSchema#string